ARIBIOLAB
Founded in 2000 and KOSDAQ-listed in 2021, AribioLAB develops next-generation vaccines using its L-pampo® and Lipo-pam® adjuvant platforms.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2000 and listed on KOSDAQ in 2021, AribioLAB is a biotech venture that joined the Cha Bio Group in 2011 when Cha Bio&Diostech became its largest shareholder. Built on its proprietary adjuvant platforms L-pampo® and Lipo-pam®, the company develops next-generation vaccines and immunotherapeutics including a chronic hepatitis B therapeutic vaccine, a hepatitis B preventive vaccine, and a recombinant herpes zoster vaccine. L-pampo® shows more than 100-fold higher antibody formation than the conventional adjuvant alum, and the company holds an S-grade patent, the highest of nine grades under the KEV patent evaluation rating system.
Products & technology
- L-pampo®TLR2/TLR3 ligand complex adjuvant that enhances immune response to vaccine antigens
- Lipo-pam®Liposomal adjuvant combining immune enhancement and antigen delivery, applied to therapeutic vaccine development
Clinical trials
data.go.kr6 MFDS clinical trial authorisations · 2012–2025 (Phase 1 2 · Phase 1/2a 2 · Phase 2 1 · Phase 2b 1)
- Phase 2CVI-VZV-0012025-12-18
7 trial sites
- Phase 1CVI-VZV-0012022-12-05
2 trial sites
- Phase 1CVI-HBV-0022021-06-02
1 trial site
- Phase 2bCVI-HBV-0022019-10-07
9 trial sites
- Phase 1/2aCVI-HBV-0022014-05-26
2 trial sites
- Phase 1/2aCVI-HBV-0012012-08-02
1 trial site
R&D and key agreements
Source: DART corporate disclosure만성 B형간염 치료백신 · 만성 B형간염 · Lead pipeline developed alongside an improved prophylactic vaccine
B형간염 예방백신 · B형간염 · Prophylactic vaccine under development with improved efficacy versus existing vaccines
재조합 대상포진 백신 · 대상포진 · One of the company lead pipeline products
노인용 독감 백신 · 인플루엔자 · Pipeline improving efficacy of existing influenza vaccines for the elderly
노로바이러스 백신 · 노로바이러스 감염증 · Development of a previously non-commercializable norovirus vaccine
항암백신 · 암 · Pipeline aimed at preventing cancer recurrence and maximizing efficacy via combination therapy
Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition